메뉴 건너뛰기




Volumn 114, Issue 3, 2001, Pages 734-735

Advanced-stage, chemorefractory lymphocyte-predominant Hodgkin's disease: Long-term follow-up of allografting and monoclonal antibody therapy [3]

Author keywords

Allogeneic transplantation; Anti CD20; Chemorefractory; Lymphocyte predominant Hodgkin's disease; Rituximab

Indexed keywords

BLEOMYCIN; CARMUSTINE; CHLORAMBUCIL; CYCLOSPORIN A; CYTARABINE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; IFOSFAMIDE; MELPHALAN; METHOTREXATE; MONOCLONAL ANTIBODY; PREDNISOLONE; PROCARBAZINE; RITUXIMAB; THYMOCYTE ANTIBODY; VINBLASTINE; VINCRISTINE;

EID: 0034800377     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter
Times cited : (10)

References (7)
  • 7
    • 0008915087 scopus 로고    scopus 로고
    • Monoclonal anti-CD20 antibody Rituximab (Rituxan) for treatment of CD20-positive Hodgkin's lymphoma: The German experience
    • (2000) Blood , vol.96
    • Rehwald, U.1    Engert, A.2    Diehl, V.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.